Company intelligence / Profile preview

Synexis

Lenexa, Kansas, United Statessynexis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Synexis's DHP® technology has demonstrated >99.99% reduction of the Delta variant of SARS-CoV‑2 in air within 90 minutes and 98.7% on surfaces within four hours in controlled studies; additional data show significant reductions in hospital-acquired infection rates and microbial contamination on privacy curtains in healthcare settings. The system operates continuously to reduce pathogens without disrupting room occupancy.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: DeviceNon-pharmacological therapy (air and surface microbial reduction device)
Industry: Therapeutic Medical Devices

Partnerships

Diversey (strategic partnership for environmental quality solutions)

Beyond the preview

Go deeper on Synexis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synexis.

Explore the full profile